Has Soubrata Raikar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $37,516 in general payments to Soubrata Raikar, MD across 313 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Soubrata Raikar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Soubrata Raikar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Soubrata Raikar, MD

Interventional Pain Medicine · Fremont, NENPI 1154495125

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Spinefrontier, Inc. at 52.4% of the total.

$37,516in general payments, 2019–2025

Across 313 payments — averaging $119.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Spinefrontier, Inc.$20K
Biotronik NRO, Inc.$7K
Flowonix Medical Incorporated$5K
Medtronic$1K
Forte Bio-pharma LLC$950
Boston Scientific$828
plus $2K from 31 others

What the payments were for

Consulting fees$2,7007%
Speaking & faculty fees$18,12248%
Travel & lodging$6,64518%
Food & beverage$10,04927%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Spinefrontier, Inc.	31	$19,643
Biotronik NRO, Inc.	46	$7,261
Flowonix Medical Incorporated	3	$5,180
Medtronic	29	$1,274
Forte Bio-pharma LLC	68	$950
Boston Scientific	30	$828
Vertiflex, Inc.	11	$323
Nevro Corp.	19	$300
Stimwave Technologies Incorporated	4	$259
Zavation Medical Products, LLC	4	$233
Collegium Pharmaceutical, Inc.	9	$149
Si-bone, Inc.	6	$119
Nalu Medical, Inc.	4	$100
AbbVie	4	$79
Pfizer	6	$76
Spinal Simplicity, LLC	2	$72
Sunovion Pharmaceuticals Inc.	5	$56
Xtant Medical Inc	1	$54
Protega Pharmaceutials Inc	2	$52
Abbott	3	$51
Lundbeck LLC	2	$48
SPR Therapeutics, Inc	2	$45
Kowa Pharmaceuticals America, Inc.	3	$44
Biohaven Pharmaceutical Holding Company Ltd.	2	$40
Pacira Pharmaceuticals Incorporated	2	$35
Mercury Enterprises, Inc.	1	$31
GRT US Holding, Inc.	2	$31
Lilly USA, LLC	2	$31
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$31
Biohaven Pharmaceuticals, Inc.	1	$22
Scilex Pharmaceuticals Inc.	1	$19
Bioventus LLC	1	$15
Vertos Medical, Inc.	1	$15
Shionogi Inc	1	$15
CSL Behring	1	$13
Teva Pharmaceuticals USA, Inc.	1	$12
Biodelivery Sciences International, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

InSpan$19,032
SIJFuse$7,773
NanoFuse$7,773
Sacrix$6,759
Prospera$6,478
NanoFUSE Bioactive Matrix$5,605
Prometra II$5,180
SIJ Fuse$4,500
PedFuse$4,500
FacetFuse$495
Prolate$487
INTELLIS ADAPTIVESTIM$297
NA$245
VANTA ADAPTIVESTIM$200
Superion Indirect Decompression System$150
Nalocet$122
Superion ISS$115

How this compares

Too few interventional pain medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$54,569

Medicare patients

123

Services billed

1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	119	$99,272
OxycontinOxycodone Hcl	16	$6,132
MovantikNaloxegol Oxalate	11	$5,446
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	119	$5,328
Hydromorphone Hcl	65	$4,467
Dronabinol	17	$1,971
Carisoprodol	27	$1,405
Pregabalin	66	$1,087
Gabapentin	80	$982
Morphine Sulfate	36	$823
Oxycodone Hcl	53	$808
Cyclobenzaprine Hcl	71	$736
Duloxetine Hcl	43	$719
Morphine Sulfate ErMorphine Sulfate	29	$709
Tizanidine Hcl	56	$664

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Fremont

Clayton DammeLincoln$21K
Pravardhan BirthiGrand Island$19K
Kelly ZachLincoln$15K
Thomas BrooksElkhorn$13K
Rafal KrejzaOmaha$13K
Jery InbarasuOmaha$12K
Kevin BalterOmaha$11K
Madhuri AreOmaha$904

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →